Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: Results of the CANWARD 2007-2009 study

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 3, 2011, Pages 326-334

  Simner, Patricia J ^a   Zhanel, George G ^a   Pitout, Johann ^b   Tailor, Franil ^a   McCracken, Melissa ^c   Mulvey, Michael R ^a,c   Lagacé Wiens, Philippe R S ^a,d   Adam, Heather J ^a,d   Hoban, Daryl J ^a,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d Diagnostic Services of Manitoba Inc   (Canada)

Author keywords

AmpC; E. coli; ESBL

Indexed keywords

AMIKACIN; BETA LACTAMASE AMPC; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; NITROFURANTOIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENOME; BACTERIUM ISOLATE; ENZYME ANALYSIS; ESCHERICHIA COLI; GENOTYPE; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CANADA; CHILD; CHILD, PRESCHOOL; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 79951888752     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.029     Document Type: Article

References (20)

1. Baudry P.J., Nichol K., DeCorby M., Mataseje L., Mulvey M.R., Hoban D.J., Zhanel G.G. Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrob. Agents Chemother. 2008, 52:1846-1849.
2. Baudry P.J., Nichol K., DeCorby M., Lagacé-Wiens P., Olivier E., Boyd D., Mulvey M.R., Hoban D.J., Zhanel G.G. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America. Diagn. Microbiol. Infect. Dis. 2009, 63:319-326.
3. Baudry P.J., McCracken M., Lagacé-Wiens P., Mulvey M.R., Zhanel G.G., Hoban D.J. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Canadian hospitals: results from CANWARD 2007. Can. J. Infect. Dis. Med. Microbiol. 2009, 20(Suppl A):43A-47A.
4. Baudry P.J., Mataseje L., Zhanel G.G., Hoban D.J., Mulvey M.R. Characterization of plasmids encoding CMY-2 AmpC β-lactamases from Escherichia coli in Canadian intensive care units. Diagn. Microbiol. Infect. Dis. 2009, 65:379-383.
5. Caroff N., Espaze E., Bérard I., Richet H., Reynaud A. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production. FEMS Microbiol. Lett. 1999, 173:459-465.
6. Clermont O., Dhanji H., Upton M., Gibreel T., Fox A., Boyd D., Mulvey M.R., Nordmann P., Ruppé E., Sarthou J.L., Frank T., Vimont S., Arlet G., Branger C., Woodford N., Denamur E. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J. Antimicrob. Chemother. 2009, 64:274-277.
7. Clinical and Laboratory Standards Institute Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard seventh edition; M07-A7 2006, CLSI, Wayne, PA.
8. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 18th informational supplement document M100-S16 2010, CLSI, Wayne, PA.
9. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E., Hsueh P.R., Paterson D.L. Emergence of high levels of extended-spectrum-beta-lactamase-producing Gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob. Agents Chemother. 2009, 53:3280-3284.
10. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int. J. Antimicrob. Agents 2009, 34:585-588.
11. Hoban D.J., Zhanel G.G. Introduction to the CANWARD study, 2007-2009. Diagn. Microbiol. Infect. Dis. 2011, 69:289-290.
12. Mulvey M.R., Bryce E., Boyd D., Ofner-Agostini M., Christianson S., Simor A.E., Paton S. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob. Agents Chemother. 2004, 48:1204-1214.
13. Mulvey M.R., Bryce E., Boyd D.A., Ofner-Agostini M., Land A.M., Simor A.E., Paton S. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob. Agents Chemother. 2005, 49:358-365.
14. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 2005, 18(4):657-686.
15. Peirano G., Richardson D., Nigrin J., McGeer A., Loo V., Toye B., Alfa M., Pienaar C., Kibsey P., Pitout J.D.D. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-β-lactamase-producing Escherichia coli isolates from Canada. Antimicrob. Agents Chemother. 2010, 54:1327-1330.
16. Perez-Perez F.J., Hanson N.D. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 2002, 40:2153-2162.
17. Pitout J.D., Gregson D.B., Church D.L., Laupland K.B. Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg. Infect. Dis. 2007, 13:443-448.
18. Pitout J.D.D. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert. Rev. 2008, 6:657-669.
19. Zhanel G.G., Adam H.J., Low D.E., Blondeau J., DeCorby M., Karlowsky J., Weshnoweski B., Vashisht R., Wierzbowski A., the Canadian Antimicrobial Resistance Alliance, Hoban D.J. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 2011, 69:291-306.
20. Zhanel G.G., DeCorby M., Laing N., Weshnoweski B., Vashisht R., Tailor F., Nichol K.A., Wierzbowski A., Baudry P.J., Karlowsky J.A., Lagacé-Wiens P., Walkty A., McCracken M., Mulvey M.R., Johnson J., Hoban D.J. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob. Agents Chemother. 2008, 52:1430-1437. Canadian Antimicrobial Resistance Alliance (CARA).